Perrier Quentin, Lisi Veronica, Fisherwellman Kelsey, Lablanche Sandrine, Asthana Amish, Orlando Giuseppe, Maiocchi Sophie
Department of Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston Salem, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, USA; Univ. Grenoble Alpes, INSERM U1055, Pharmacy Department, Grenoble Alpes University Hospital, LBFA, Grenoble, France.
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, USA; Department of Biomedical Engineering, Wake Forest University School of Medicine, Winston Salem, USA.
Free Radic Biol Med. 2025 Oct;238:473-495. doi: 10.1016/j.freeradbiomed.2025.06.040. Epub 2025 Jun 24.
Mitochondrial and extracellular vesicles (EV) transplantation have emerged as promising therapeutic strategies targeting mitochondrial dysfunction, a central feature of numerous pathologies. This review synthesizes preclinical data on artificial mitochondrial and EV transfer, emphasizing their therapeutic potential and underlying mechanisms. A systematic analysis of 123 animal studies revealed consistent benefits across diverse models, including ischemia-reperfusion injury (IRI), neurological disorders, drug-induced toxicities, and sepsis. Mitochondrial transfer improved organ function, reduced inflammation and apoptosis, and enhanced survival. Mechanistic insights revealed restored bioenergetics, increased oxidative phosphorylation, redox balance through activation of specific pathways, and modulation of mitochondrial dynamics via fusion/fission proteins. Mitochondrial homeostasis was supported through elevated mitophagy and biogenesis, alongside the preservation of mitochondrial-associated membranes. EV demonstrated similar effects, offering a potentially more targeted therapeutic alternative. Although pre-clinical studies have demonstrated safety and feasibility, broader application is limited by variability in isolation methods, lack of mechanistic clarity, and minimal human data. Standardization and mechanistic validation are critical to advance clinical translation. This review underscores the therapeutic promise of mitochondrial and EV transfer while highlighting the need for continued research to refine these interventions and unlock their full potential in regenerative medicine.
线粒体和细胞外囊泡(EV)移植已成为针对线粒体功能障碍的有前景的治疗策略,线粒体功能障碍是众多疾病的核心特征。本综述综合了关于人工线粒体和EV转移的临床前数据,强调了它们的治疗潜力和潜在机制。对123项动物研究的系统分析显示,在包括缺血再灌注损伤(IRI)、神经系统疾病、药物诱导的毒性和脓毒症等多种模型中都有一致的益处。线粒体转移改善了器官功能,减少了炎症和细胞凋亡,并提高了存活率。机制研究揭示了生物能量恢复、氧化磷酸化增加、通过特定途径激活实现氧化还原平衡以及通过融合/裂变蛋白调节线粒体动力学。通过增强线粒体自噬和生物合成以及保留线粒体相关膜来支持线粒体稳态。EV显示出类似的效果,提供了一种可能更具靶向性的治疗选择。尽管临床前研究已证明其安全性和可行性,但更广泛的应用受到分离方法的变异性、机制清晰度不足以及人类数据极少的限制。标准化和机制验证对于推进临床转化至关重要。本综述强调了线粒体和EV转移的治疗前景,同时强调需要持续研究以优化这些干预措施并释放它们在再生医学中的全部潜力。